Supreme Court Faces Urgent Appeal on Access to Abortion Pill Mifepristone

Want the full story?
Read the complete article at KVIA
AI Summary
The manufacturers of mifepristone, a key abortion pill, have filed an emergency appeal with the Supreme Court following a recent ruling by the 5th US Circuit Court of Appeals. This ruling reinstated a requirement for the drug to be obtained in person, which could significantly limit access for many women seeking abortions, especially as medication abortions have surged to over 60% of total abortions in the US in 2023. Danco Laboratories argues that the decision creates immediate confusion for patients relying on telehealth services. The Supreme Court's response is crucial as it could impact the availability of the drug nationwide.
Key Details: • Emergency appeal filed on Saturday with Justice Samuel Alito. • 5th Circuit ruling requires in-person acquisition of mifepristone. • Medication abortions have become more common since Roe v. Wade was overturned. • Over 60% of abortions in the US in 2023 were medication-based. • Danco Laboratories seeks an immediate stay on the 5th Circuit's decision.